Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508116 · ClinicalTrials.gov registry record · NA
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention
A NA study of Cardiovascular Diseases and Acute Coronary Syndrome, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 509
- Enrollment target
- 2
- Study locations
NCT02508116: Completed NA study of Cardiovascular Diseases and Acute Coronary Syndrome, sponsored by University of Pennsylvania.
NCT02508116 is a NA study of Cardiovascular Diseases and Acute Coronary Syndrome that has completed, run by University of Pennsylvania. The registered enrollment target is 509 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508116, a NA study of Cardiovascular Diseases and Acute Coronary Syndrome, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 509 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, prospective, open label study to determine the cost-effectiveness of genotype-guided antiplatelet therapy. Patients undergoing percutaneous intervention (PCI) with stent implantation, will be randomized either to genotype guided dosing of antiplatelet therapy or usual care. The study utilizes a novel genotyping device, SpartanRx, to determine CYP2C19 genotypes from a buccal swab sample with 1 hour turnaround time.
Primary Outcome
The number (percentage) of participants receiving prasugrel/ticagrelor in each randomized arm
Conditions Studied
Interventions
- GENETIC CYP2C19 genotyping
Study Locations (2)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-08 |
| Phase | NA |
What the finished NCT02508116 record still lists
NCT02508116 is an interventional study that assigns participants to a tested intervention. The registered 509 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which CYP2C19 genotyping is the first listed.
NCT02508116 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02508116 about?
NCT02508116 is a clinical study titled "Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention". This is a randomized, prospective, open label study to determine the cost-effectiveness of genotype-guided antiplatelet therapy. Patients undergoing percutaneous intervention (PCI) with stent implantation, will be randomized either to genotype guided dosing of antiplatelet therapy or usual care. The...
What is the current status of trial NCT02508116?
This trial is currently completed. It is a NA study. The enrollment target is 509 participants. The study started on 2014-11. Estimated completion is 2017-08.
What conditions does trial NCT02508116 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Acute Coronary Syndrome.
What interventions are being tested in trial NCT02508116?
The interventions under investigation include: CYP2C19 genotyping (GENETIC).
Who is sponsoring clinical trial NCT02508116?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02508116 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02508116's enrollment target sits among peer trials
509 92nd of 300 higher than 209 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia